Clinical trial · Observational
Microbiotic Analysis in Digestive Endocrine Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Incidence of digestive neuroendocrine tumors are increasing. Analysis of individual microbiota is a way to explore new neoplastic mechanisms, tumor identification and therapeutic orientations. This prospective pilot study aims to describe fecal bacterial phylogeny of patients with digestive neuroendocrine tumor. Bacterial genomic signature will be recorded at initiation of Lanreotide treatment in naive patient with digestive neuroendocrine tumor (pancreas or small intestine), metastatic or locally advanced, as well as after one year follow up.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bacterial Signature | — | UNRESOLVED | — |
| Digestive Neuroendocrine Tumor | — | UNRESOLVED | — |
| Fecal Microbiota | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological sampling | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patient with digestive neuroendocrine tumor
- description
- naive patient with digestive neuroendocrine tumor (pancreas or small intestine), initiating Lanreotide treatment
- interventionNames
- Biological: Biological sampling
- label
- Patient without tumor
- description
- Historical control group (retrospective data) Patients, with normal endoscopic and body imaging results, having had fecal ARN16s sequencing who were assigned as control subjects for microbiota analyses.
Primary outcomes (1)
- measure
- bacterial genomic signature
- timeFrame
- Baseline visit
- description
- bacterial genomic signature by fecal ARN16S analysis at enrollment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years old or older * naive patient with digestive neuroendocrine tumor (pancreas (cytology or histology per endoscopy or on surgical specimen) or small intestine), secreting or not, initiating a extended release Lanreotide treatment * registered with a social security scheme Exclusion Criteria: * medical contraindication to somatostatine analogs use * history of extended release somatostatine analogs treatment * antibiotic use or colonoscopic purge in the last 3 weeks preceding fecal sample * pregnant or breastfeeding women * person requiring tutorship, guardianship, or person legally protected
References
Publications (0)
Data not yet available